Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.

Journal of hepatology·2026
Same author

Outcomes With Immunotherapy in Hormone Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis.

American journal of clinical oncology·2026
Same author

Management of Recurrent Venous Thromboembolism on Anticoagulation.

Journal of clinical medicine·2026
Same author

No shots needed: direct oral anticoagulants in cancer-associated thrombosis-10-year follow-up.

Hematology. American Society of Hematology. Education Program·2025
Same author

Liquid biopsy and health-related quality of life in cancers: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

[<sup>18</sup>F]FDG-PET provides insights into the liver-brain axis and confirms SUV<sub>gluc</sub> as a surrogate for MR<sub>Glu</sub> in a mouse model of liver fibrosis.

Nuclear medicine and biology·2025

Related Experiment Video

Updated: Mar 26, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

55.3K

Temozolomide-induced biliary ductopenia: a case report.

Asha Balakrishnan1, Robert Ledford2, Michael Jaglal3,4

  • 1Department of Internal Medicine, University of South Florida, Tampa, FL, USA. ashab@health.usf.edu.

Journal of Medical Case Reports
|February 6, 2016
PubMed
Summary

Temozolomide therapy for glioblastoma can cause liver injury, specifically biliary ductopenia. Careful monitoring of liver function tests is crucial during treatment to detect and manage this rare adverse effect.

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.7K
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

55.3K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.7K
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K

Area of Science:

  • Oncology
  • Hepatology
  • Pharmacology

Background:

  • Temozolomide is a standard alkylating agent for glioblastoma treatment, often combined with radiation.
  • Bone marrow suppression is the primary adverse effect, but hepatotoxicity, including liver failure, has been reported.
  • This report details a unique mechanism of temozolomide-induced liver injury with histopathological evidence.

Observation:

  • A 58-year-old woman with glioblastoma developed worsening transaminitis and bilirubinemia after 6 weeks of temozolomide and radiation.
  • Liver biopsy confirmed drug-induced cholestasis and ductopenia.
  • Following drug cessation, hyperbilirubinemia progressed, and a repeat biopsy showed severe biliary ductopenia, consistent with vanishing bile duct syndrome.

Findings:

  • Temozolomide can induce severe cholestatic liver injury and biliary ductopenia, a rare but serious adverse effect.
  • The patient's liver injury progressed despite drug discontinuation, indicating a potentially severe and persistent reaction.
  • Histopathology confirmed vanishing bile duct syndrome as a consequence of temozolomide treatment.

Implications:

  • Close monitoring of liver function tests (LFTs) is essential during temozolomide and radiation therapy for glioblastoma.
  • Clinicians should be vigilant for signs of cholestatic liver injury, including elevated bilirubin and transaminases.
  • Minimizing co-administration of other hepatotoxic drugs metabolized by the liver is recommended during chemoradiation.